https://www.selleckchem.com/pr....oducts/almorexant-hc
006). Two patients (1.1%) developed vision loss, both at the initiation of TCZ treatment. Our data show a very low incidence of vision loss in TCZ-treated patient. The two cases of AION occurred at the initiation of therapy, they support the hypothesis that advanced, and established structural changes of arteries are key factors for this accident. Whether a shorter duration of concomitant GC treatment is risky regarding vision loss needs to be studied. Our data show a very low incidence of vision loss in TCZ-treated patient. The
Curtir
Comentario
Compartilhar
